W

Wichita Urology Group | Wichita, KS

Research site
(Unclaimed)
Location
2626 N Webb Road, Wichita, Kansas, United States of America
Site insights

Top conditions

Urinary Bladder Cancer (6 trials)

Non-Muscle Invasive Bladder Cancer (5 trials)

Prostatic Cancer (5 trials)

Transitional Cell Carcinoma (2 trials)

Carcinoma (2 trials)

Top treatments

TAR-200
UGN-102
Androgen
Vibegron
Cetrelimab
Apalutamide
docetaxel
Testosterone
Nivolumab
Leuprolide Acetate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

7 of 13
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

This Phase 3, multinational, single-arm, multicenter study will evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patie...

Active, not recruiting
Bladder Cancer
Urothelial Carcinoma
Drug: UGN-102

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Enrolling
Bladder Cancer
Biological: Cetrelimab
Biological: BCG Vesiculture

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab...

Enrolling
Urinary Bladder Neoplasms
Biological: Cetrelimab
Drug: TAR-200

The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC

Enrolling
Neurogenic Detrusor Overactivity
Drug: Vibegron

A pivotal study to evaluate the safety and effectiveness of Applaud Acoustic Enhancer when used in conjunction with conventional ureteroscopic laser...

Active, not recruiting
Urinary Stones
Device: Standard Ureteroscopic Laser Lithotripsy
Device: Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer

A Phase 1/2a, open-label, multicenter study of intramuscular (i.m.) PRL-02 depot in participants with advanced prostate cancer.

Enrolling
mCSPC
mCRPC
Drug: prednisone
Drug: dexamethasone

This is a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. This st...

Active, not recruiting
Prostate Cancer
Drug: Leuprolide Acetate
Drug: Relugolix

Trial sponsors

Janssen logo

Janssen (3 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems